RxDoctor Payments DataLook up a doctor →

Jonathan Reitman, MD

Addiction Medicine · Beverly Hills, CANPI 1922157320

Payments from drug & device makers

$11,447in general payments, 2019–2025

Across 539 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Gilead$2K
  • Viiv Healthcare Company$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$885
  • Indivior Inc.$501
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$500
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$831%
  • Food & beverage$11,36499%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,447 in reported general payments places this provider in the 95th percentile of 190 addiction medicine providers in California.

See all addiction medicine providers in California

Medicare billing

Part B allowed, 2024
$408,971
Medicare patients
180
Services billed
7,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SerostimSomatropin71$1,653,499
BiktarvyBictegrav/Emtricit/Tenofov Ala58$237,035
Sodium Oxybate11$135,172
Gamunex-CImmune Globul G/Gly/Iga Avg 4622$123,613
CabenuvaCabotegravir/Rilpivirine18$117,397
DescovyEmtricitabine/Tenofov Alafenam36$78,889
SuboxoneBuprenorphine Hcl/Naloxone Hcl54$40,423
Levorphanol Tartrate12$38,983
IsentressRaltegravir Potassium13$25,510
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl109$20,937
RexultiBrexpiprazole14$20,715
VivitrolNaltrexone Microspheres13$20,463
JardianceEmpagliflozin18$18,605
AuvelityDextromethorphan Hbr/Bupropion12$13,406
BelsomraSuvorexant26$10,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Serostim$442$1,653,49971 claims
GileadBiktarvy, Descovy$1,803$315,92494 claims
Viiv Healthcare CompanyCabenuva$1,353$117,39718 claims
Indivior Inc.Suboxone$501$40,42354 claims
MerckIsentress, Belsomra$137$36,48139 claims
Otsuka America Pharmaceutical, Inc.Rexulti$250$20,71514 claims
Alkermes, Inc.Vivitrol$25$20,46313 claims
Axsome Therapeutics, Inc.Auvelity$97$13,40612 claims
AbbVieRestasis, Creon$2,325$10,55524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 190 addiction medicine providers in California.

Other addiction medicine in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →